NEOPLASIAS MIELOIDES: DETECCIÓN DE DELECIÓN del(5q31) - gen EGR1 - CIDEGEN
Cidegen
Delivery time
Resultados: <1 semana desde la recepción de la muestra.
Sample
Sangre (EDTA), Médula ósea (EDTA), Tejido parafinado (FFPE)
167,00€
Deletion present in 10% of patients with myelodysplastic syndrome. A favorable prognostic marker. Treatment with lenalidomide. Associated with non-lobulated megakaryocytes, macrocytic anemia, and normal or increased platelets. EGR1 analysis.